home / stock / sls / sls news

SLS News and Press, SELLAS Life Sciences Group Inc. From 10/12/23

Stock Information
Company Name: SELLAS Life Sciences Group Inc.
Stock Symbol: SLS
Market: NASDAQ
Website: sellaslifesciences.com
Menu
SLS SLS Quote SLS Short SLS News SLS Articles SLS Message Board
Get SLS Alerts

News, Short Squeeze, Breakout and More Instantly...
SLS - BYND, SLS and WHLR among pre-market losers

2023-10-12 08:22:14 ET More on Beyond Meat, SELLAS Life Sciences, etc. Beyond Meat Continues To Look Potentially Beyond Repair Beyond Meat: The Core Question Here Is Liquidity Beyond Meat: Pain Is Far From Over SELLAS gains on FDA orphan drug status for its S...
SLS - SELLAS gains on FDA orphan drug status for its SLS009

2023-10-11 09:05:14 ET More on SELLAS Life Sciences SELLAS Phase 3 study for AML drug to continue without modifications Seeking Alpha’s Quant Rating on SELLAS Life Sciences For further details see: SELLAS gains on FDA orphan drug status for its SLS009

SLS - SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...

SLS - SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...
SLS - Solaris Appoints CICC as Chinese Financial Advisor

VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) announces the appointment of China International Capital Corporation Limited (“CICC”) as the Company’s ...

SLS - SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

- 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable Survival Benefit - - Responses Observed Across Dose Levels with a 14.7% Clinical Response Rate Overall, 35.3% Overall Disease Control Rate, and 36.4% Clinical Response Rate in PT...

SLS - SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelo...
SLS - Solaris Reports 96m of 0.59% CuEq From Near Surface within 144m of 0.50% CuEq and 148m of 0.52% CuEq in First Two Reconnaissance Holes at Patrimonio

VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce assay results from the first two reconnaissance drill holes at the Patrimonio target confirming a si...

SLS - SELLAS Phase 3 study for AML drug to continue without modifications

2023-08-22 10:24:41 ET More on SELLAS Life Sciences SELLAS falls 39% after delaying key milestone for cancer drug Sellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trial SELLAS Life Sciences rises 9% after cancer drug shows ...

SLS - SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications

REGAL Interim Analysis Expected by Late 2023/Early 2024 Enrollment Expected to be Completed in Q4 2023 NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical bi...
Previous 10 Next 10